General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: www.iiar-anticancer.org

Selection of Recent Articles

Small Molecule GS-Nitroxide Ameliorates Ionizing Irradiation-Induced Delay in Bone Wound Healing in a Novel Murine Model. A. GORHALE, J.-C. RWIGEMA, M. EPPERLY, J. GLOWACKI, W. WIPF, J. GOFF, T. DIXON, K. PATRENE, J. GREENBERGER (Pittsburgh, PA; Boston, MA, USA)


Effects of Voluntarily Ingested Buprenorphine on Plasma Corticosterone Levels, Body Weight, Water Intake, and Behavior in Permanently Catheterised Rats. R. GOLDRUHL, J. HAU, K.S.P. ABELSON (Uppsala, Sweden; Copenhagen, Denmark)

Pharmacologic Ascorbic Acid Suppresses Syngeneic Tumor Growth and Metastases in Hormone-Refractory Prostate Cancer. H.B. POLLARD, M.A. LEVINE, O. EIDELMAN, M. POLLARD (Bethesda, MD; Notre Dame, IN, USA)

Uterus Cryopreservation in the Sheep: One Step Closer to Uterus Transplantation. R. DITTRICH, M. POLLARD (Erlangen, Germany)

Modulation of Aged Murine T Lymphocytes In Vivo by DPV576-C, a Nanodiamond- and Nanoplatinum-coated Material. M. GHONEUM, A. GHONEUM, L. TOLENTINO, J. GIMZEWSKI (Los Angeles, CA, USA)


Effects of Fetal Exposure to 4-n-octylphenol on Mammary Tumorigenesis in Rats. H. KAWAGUCHI, N. MIYOSHI, Y. MIYAMOTO, M. SOUDA, Y. UMEKITA, N. YASUDA, H. YOSHIDA (Kagoshima, Japan)

Comparative Study of Difference Between Long and Short Pulse on Treating Melanoma In Vivo. X. CHEN, R.J. SWANSON, K.H. SCHENBA R, S. ZENG (Zhejiang, China; Nova Scotia, VA, USA)

Tetrandrine Pre-Treatment has Protective Effects Against Isoproterenol-induced Myocardial Infarction in Rabbits. A. PINELLI, S. TRIVULZIO, S. BRENNA, G. ROSSONI (Milan, Italy)

Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUN, J.M. ECHENBERG, H.-G. MACHENS, E. BIEMER (Munich; Erlangen, Germany)

Effects of Fetal Exposure to 4-n-octylphenol on Mammary Tumorigenesis in Rats. H. KAWAGUCHI, N. MIYOSHI, Y. MIYAMOTO, M. SOUDA, Y. UMEKITA, N. YASUDA, H. YOSHIDA (Kagoshima, Japan)

Comparative Study of Difference Between Long and Short Pulse on Treating Melanoma In Vivo. X. CHEN, R.J. SWANSON, K.H. SCHENBA R, S. ZENG (Zhejiang, China; Nova Scotia, VA, USA)

Tetrandrine Pre-Treatment has Protective Effects Against Isoproterenol-induced Myocardial Infarction in Rabbits. A. PINELLI, S. TRIVULZIO, S. BRENNA, G. ROSSONI (Milan, Italy)

Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUN, J.M. ECHENBERG, H.-G. MACHENS, E. BIEMER (Munich; Erlangen, Germany)
Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Serious Hematologic Complications Following Erlotinib Treatment. G.P. STATHOPOULOS, DIM. TRAFALIS, A. ATHANASIOU, G. BARDI, H. CHANDRINOU (Athens; Piraeus, Greece) ......................... 973

A New Prognostic Score Derived from Phase I Study Participants with Advanced Solid Tumours Is also Valid in Patients with Brain Metastasis. C. NIEDER, A. DALHAUG (Bodø; Tromsø, Norway) .................. 977

Mutations of PTEN Gene in Gliomas Correlate to Tumor Differentiation and Short-term Survival Rate. Y. YANG, N. SHAO, G. LUO, L. LI, L. ZHENG, P. NILSSON-EHLE, N. XU (Changzhou, China; Lund, Sweden) ...... 981

Carbonic Anhydrase IX Expression Is Associated with Improved Outcome of High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma. A.Z. DUDEK, R.T. YEE, J.C. MANIVEL, R. ISAKSSON, H.O. YEE (Minneapolis, MN, U.S.A.) ............................................................. 987

Effects of Preoperative Immunochemoradiotherapy and Chemoradiotherapy on Immune Responses in Patients with Rectal Adenocarcinoma. S. SADAHIRO, T. SUZUKI, Y. MAEDA, A. TANAKA, A. KAMIJO, C. MURAYAMA, Y. NAKAYAMA, T. AKIBA (Isehara, Japan) .................................................. 993

Front-line Bevacizumab in Serous Epithelial Ovarian Cancer: Biomarker Analysis of the FINAVAST Trial. P. KARIHTALA, J. MÄENPÄÄ, T. TURPEENNIEMI-HUJANEN, U. PUISTOLA (Oulu; Tampere, Finland) .... 1001

ELISA Measurement for Urinary 3-Hydroxyproline-containing Peptides and its Preliminary Application to Healthy Persons and Cancer Patients. J. SAITO, Y. IMAMURA, J. ITOH, S. MATSUYAMA, A. MARUTA, T. HAYASHI, A. SATO, N. WADA, K. KASHIWAZAKI, Y. INAGAKI, T. WATANABE, Y. KITAGAWA, I. OKAZAKI (Shinjuku-ku; Inagi City; Hachioji City; Tachikawa; Minato-Ku, Tokyo; Chiba City; Ichihara; Chiba; Tokorozawa, Saitama; Ebina City; Isehara City, Kanagawa, Japan) .................................................. 1007


Lysozyme Overexpression in Fundic Gland Polyps. C.A. RUBIO (Stockholm, Sweden) ........................................ 1021

Acute Pancreatitis with a Mucinous Cystoadenoma of the Pancreas in Pregnancy. S. ASCIUTTI, T.T. KANNINEN, G. CLERICI, E. NARDI, D. CASTELLANI, G.C. DI RENZO, C. CLERICI (Perugia, Italy) ........................................ 1025

Correlation Between [18F]Fluorodeoxyglucose Positron-emission Tomography Scan and Histology of Pelvic Nodes in Early-stage Cervical Cancer. E. BÉNITVEGNA, C. UZAN, S. GOUY, S. LEOBULLEUX, P. DUVILLARD, J. LUMBROSO, C. HAIE-MEDER, M. SCHLUMBERGER, P. MORICE (Villejuif, France) ........... 1029

Errata ......................................................................................................................................................... 1033

Book Reviews .............................................................................................................................................. 1035

* Reviews (pages 751, 815)
SPARC mRNA Expression as a Prognostic Marker for Pancreatic Adenocarcinoma Patients. K. MIYOSHI, N. SATO, K. OHUCHIDA, K. MIZUMOTO, M. TANAKA (Fukuoka, Japan) ............................................................ 867


LGP1, A Histone Deacetylase Inhibitor Analogue of FR235222, sensitizes Promyelocytic Leukaemia U937 Cells to TRAIL-mediated Apoptosis. C.W. D’ACUNTO, A. CARRATU, M. RODRIGUEZ, M. TADDEI, L. PARENTE, A. PETRELLA (Salerno; Siena, Italy) .................................................................................................................. 887

Yeast-based Identification of Prostate Tumor Antigens Provides an Effective Vaccine Platform. V. JUNG, E. FISCHER, J. IMIG, S. KLEBER, N. NUBER, F. REINSHAGEN, J. KAMRADT, R. GROBHOZ, A. KNUTH, C. RENNER, A. WADLE (Homburg, Germany; Zurich, Switzerland) .................................................................................................................. 895

Water-soluble Taxol Conjugates with Dextran and Targets Tumor Cells by Folic Acid Immobilization. J. NAKAMURA, N. NAKAJIMA, K. MATSUMURA, S.-H. HYON (Sakyo-ku, Kyoto, Japan) ......................................................... 903

Effects of Insulin-like Growth Factor Binding Protein 7 on Apoptosis in Human Teratocarcinoma Cells In Vitro. W. ENGSTRÖM (Oxford, U.K.; Uppsala, Sweden) .................................................................................................................. 911

Establishment and Characterization of Multidrug-resistant Gastric Cancer Cell Lines. X. ZHANG, M. YASHIRO, H. QIU, T. NISHII, T. MATSUZAKI, K. HIRAKAWA (Osaka, Japan; Beijing; Wuhan, China) .................................................................................................................. 915


Enhancement of Radiation-induced DNA Damage and Inhibition of Its Repair by a Novel Camptothecin Analog. G. HUANG, H. WANG, L.-X. YANG (San Francisco, CA, U.S.A.) .................................................................................................................. 937

Emodin, Aloe-emodin and Rhein Induced DNA Damage and Inhibited DNA Repair Gene Expression in SCC-4 Human Tongue Cancer Cells. Y.-Y. CHEN, S.-Y. CHIANG, J.-G. LIN, J.-S. YANG, Y.-S. MA, C.-L. LIAO, T.-Y. LAI, N.-Y. TANG, J.-G. CHUNG (Taichung, Taiwan, R.O.C.) .................................................................................................................. 945

Clinical Studies


Severe Intoxication with Methotrexate Possibly Associated with Concomitant Use of Proton Pump Inhibitors. R. SANTUCCI, D. LEVÈQUE, V. KEMMEL, P. LUTZ, A.-C. GÉROUT, A. N’GUYEN, A. LESCOUTE, F. SCHNEIDER, J.-P. BERGERAT, R. HERBRECHT (Strasbourg, France) .................................................................................................................. 963

Acute Promyelocytic Leukemia in Patients Aged Over 60 Years: Multicenter Experience of 34 Consecutive Unselected Patients. F. FERRARA, O. FINIZIO, A. D’ARCO, L. MASTRULLO, N. CANTORE, P. MUSTO (Naples; Nocera Inferiore; Avellino; Rionero in Vulture (Pz), Italy) .................................................................................................................. 967

Contents continued on the preceding page

Manipulation of Iron Transporter Genes Results in the Suppression of Human and Mouse Mammary Adenocarcinomas. X.P. Jiang, R.L. Elliott, J.F. Head (Baton Rouge, LA, U.S.A.) .......................................................... 759

Thioredoxin and Thioredoxin Reductase Expression in Thyroid Cancer Depends on Tumour Aggressiveness. D.T. Lincoln, F. Al-Yatama, F.M.A. Mohammed, A.G. Al-Banaw, M. Al-Bader, M. Burge, F. Sinowitz, P.K. Singal (Chapel Hill; Herston, QLD, Australia; Kuwait City, Kuwait; Munich, Germany; Winnipeg, MB, Canada) .................................................... 767


Synthetic Triterpenoids Inhibit Growth, Induce Apoptosis and Suppress Pro-survival Akt, mTOR and NF-κB Signaling Proteins in Colorectal Cancer Cells. X. Gao, D. Deeb, J. Hao, Y. Liu, A.S. Arbab, S.A. Dulchavsky, S.C. Gautam (Detroit, MI, U.S.A.) .................................................... 785

Broad Selective Efficacy of rMETase and PEG-rMETase on Cancer Cells In Vitro. Y. Tan, M. Xu, R.M. Hoffman (San Diego, CA, U.S.A.) ............................................................................................................ 793

Rapamycin-mediated FOXO1 Inactivation Reduces the Anticancer Efficacy of Rapamycin. E. Abdelnour-Berchtold, Y. Cerantola, D. Roulin, A. Dordon-Meulwy, N. Demartines, O. Dordon (Lausanne, Switzerland) ............................................................................................................ 799

Differential Expression of VEGF121, VEGF165 and VEGF189 in Angiomas and Squamous Cell Carcinoma Cell Lines of the Head and Neck. C. Cai, M.C. Bottcher, J.A. Werner, R. Mandic (Marburg, Germany) .................................................... 805

Evaluation of Liposomal Curcumin Cytochrome P450 Metabolism. C.M. Mach, J.H. Chen, S.A. Mosley, R. Kurzrock, J.A. Smith (Houston, TX, U.S.A.) ............................................................................................................ 811


Constituents of Carpobrotus edulis Inhibit P-Glycoprotein of MDR1-transfected Mouse Lymphoma Cells. A. Martins, A. Vasas, ZS. Schelz, M. Viveiros, J. Molnár, J. Hoehmann, L. Amaral (Lisbon, Portugal; Szeged, Hungary) ............................................................................................................ 829

Estimation of Relationship between the Structure of Trihaloacetylazulene Derivatives Determined by a Semiempirical Molecular-Orbital Method (PM5) and their Cytotoxicity. M. Ishihara, H. Wakabayashi, N. Motohashi, H. Sakagami (Sakado, Saitama; Kiyose, Tokyo, Japan) ............................................................................................................ 837

Calcium Glucarate Inhibits DMBA-induced Oral Carcinogenesis in the Hamster: Histomorphometric Evaluation. C. Lajolo, A. Sgambato, E. Maioranó, A. Lucchesce, S. Capodiferro, G. Favia, M. Giuliani (Rome; Bari, Italy) ............................................................................................................ 843

Significance of Karyopherin-α 2 (KPNA2) Expression in Esophageal Squamous Cell Carcinoma. M. Sakai, M. Sohda, T. Miyazaki, S. Suzuki, A. Sanó, N. Tanaka, T. Inose, M. Nakajima, H. Kato, H. Kuwano (Maebashi, Gunma; Shimotsuga-gun, Tochigi, Japan) ............................................................................................................ 851


Contents continued on the preceding page